DK2364308T3 - Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10 - Google Patents

Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10

Info

Publication number: DK2364308T3
Authority: DK; Denmark
Prior art keywords: phosphodiesterase; inhibitors; pyrazine compounds; pyrazine; compounds
Prior art date: 2008-11-14

Application number

DK09752705.5T

Other languages

English (en)

Inventor

Ning Chen

Essa Hu

Roxanne Kunz

Shannon Rumfelt

Jennifer R Allen

Matthew P Bourbeau

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-14

Filing date

2009-11-16

Publication date

2013-02-04

2009-11-16 Application filed by Amgen Inc filed Critical Amgen Inc

2013-02-04 Application granted granted Critical

2013-02-04 Publication of DK2364308T3 publication Critical patent/DK2364308T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Addiction (AREA)
Hematology (AREA)
Psychology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK09752705.5T 2008-11-14 2009-11-16 Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10 DK2364308T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11456708P	2008-11-14	2008-11-14
US16621209P	2009-04-02	2009-04-02
PCT/US2009/064637 WO2010057121A1 (en)	2008-11-14	2009-11-16	Pyrazine compounds as phosphodiesterase 10 inhibitors

Publications (1)

Publication Number	Publication Date
DK2364308T3 true DK2364308T3 (da)	2013-02-04

Family

ID=41478512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09752705.5T DK2364308T3 (da)	2008-11-14	2009-11-16	Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10

Country Status (30)

Country	Link
US (4)	US8053438B2 (da)
EP (1)	EP2364308B1 (da)
JP (1)	JP5746972B2 (da)
KR (1)	KR20110083746A (da)
CN (1)	CN102300860B (da)
AR (1)	AR074358A1 (da)
AU (1)	AU2009313768B2 (da)
BR (1)	BRPI0922095A2 (da)
CA (1)	CA2742993C (da)
CL (1)	CL2011001094A1 (da)
CO (1)	CO6382157A2 (da)
CR (1)	CR20110326A (da)
CY (1)	CY1113680T1 (da)
DK (1)	DK2364308T3 (da)
EA (1)	EA019206B1 (da)
ES (1)	ES2397218T3 (da)
HR (1)	HRP20130054T1 (da)
IL (1)	IL212687A0 (da)
MA (1)	MA32889B1 (da)
MX (1)	MX2011005100A (da)
NZ (1)	NZ592508A (da)
PE (1)	PE20110581A1 (da)
PL (1)	PL2364308T3 (da)
PT (1)	PT2364308E (da)
RS (1)	RS52598B (da)
SI (1)	SI2364308T1 (da)
SM (1)	SMT201200061B (da)
TN (1)	TN2011000221A1 (da)
TW (1)	TWI396689B (da)
WO (1)	WO2010057121A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AU2009333214B2 (en) *	2008-12-17	2013-09-26	Amgen Inc.	Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
BRPI1008498B8 (pt)	2009-02-05	2021-05-25	Takeda Pharmaceuticals Co	compostos de piridazinona úteis como inibidores da fosfodiesterase 10a, composição farmacêutica, e, uso de um composto
CN102595902B (zh) *	2009-05-12	2015-04-29	阿尔巴尼分子研究公司	7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
MX2011011900A (es)	2009-05-12	2012-01-20	Squibb Bristol Myers Co	Formas cristalinas de (s)-7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4 -(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y usos de las misma.
MA34007B1 (fr)	2010-02-19	2013-02-01	Boehringer Ingelheim Int	Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
AU2011270994B2 (en)	2010-06-24	2015-12-10	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
WO2012018058A1 (ja)	2010-08-04	2012-02-09	武田薬品工業株式会社	縮合複素環化合物
WO2012018909A1 (en)	2010-08-04	2012-02-09	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds
EP2604597B1 (en)	2010-08-10	2017-01-04	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
MX366318B (es)	2010-11-19	2019-07-05	Ligand Pharm Inc	Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
CN107141309A (zh)	2011-01-11	2017-09-08	桑诺维恩药品公司	杂芳基化合物及其使用方法
JP5973990B2 (ja) *	2011-03-16	2016-08-23	武田薬品工業株式会社	縮合複素環化合物
TWI570122B (zh)	2011-06-22	2017-02-11	武田藥品工業股份有限公司	稠合雜環化合物之結晶
US9750705B2 (en) *	2012-08-31	2017-09-05	The Regents Of The University Of California	Agents useful for treating obesity, diabetes and related disorders
CN102911135B (zh) *	2012-10-18	2016-01-13	内蒙古工业大学	2-巯基苯并噻唑类衍生物的合成方法
WO2014123899A1 (en)	2013-02-05	2014-08-14	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
US9464076B2 (en)	2013-03-15	2016-10-11	Daiichi Sankyo Company, Limited	Benzothiophene derivative
US10039764B2 (en)	2013-07-12	2018-08-07	University Of South Alabama	Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
EP3049086A4 (en)	2013-09-27	2017-02-22	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
US9657015B2 (en)	2014-07-31	2017-05-23	Boehringer Ingelheim International Gmbh	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
CN104649882A (zh) *	2015-02-11	2015-05-27	南通恒盛精细化工有限公司	一种磷酸二酯酶抑制剂的中间体制备工艺
US10807983B2 (en)	2015-03-16	2020-10-20	Ligand Pharmaceuticals, Inc.	Imidazo-fused heterocycles and uses thereof
KR20180052635A (ko) *	2015-09-18	2018-05-18	가켄 세이야쿠 가부시키가이샤	바이아릴 유도체 및 이를 포함하는 약제
CN117586272A (zh) *	2018-01-19	2024-02-23	苏州信诺维医药科技股份有限公司	杂环化合物、制备方法及其在医药上的应用
CN109020977B (zh) *	2018-10-26	2020-11-13	安庆奇创药业有限公司	一种Acalabrutinib的制备方法
US12359128B2 (en)	2020-12-17	2025-07-15	Merck Patent Gmbh	Heteroaromatic isothiocyanates
CN113929598A (zh) *	2021-11-24	2022-01-14	上海吉奉生物科技有限公司	一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法
CN117024405A (zh) *	2022-05-09	2023-11-10	浙江同源康医药股份有限公司	多环类化合物及其用途
CN115894181A (zh) *	2022-09-30	2023-04-04	渭南高新区海泰新型电子材料有限责任公司	一种环己烯基环己基二氟苯类液晶化合物的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4198417A (en)	1979-01-10	1980-04-15	American Hoechst Corporation	Phenoxyphenylpiperidines
EP1635828B1 (en)	2003-04-04	2008-04-23	H. Lundbeck A/S	4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
DE10337942A1 (de)	2003-08-18	2005-03-17	Merck Patent Gmbh	Aminobenzimidazolderivate
DE10344223A1 (de)	2003-09-24	2005-04-21	Merck Patent Gmbh	1,3-Benzoxazolylderivate als Kinase-Inhibitoren
DE10349587A1 (de)	2003-10-24	2005-05-25	Merck Patent Gmbh	Benzimidazolylderivate
US7470712B2 (en)	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
WO2005116009A1 (en) *	2004-05-18	2005-12-08	Schering Corporation	Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
CA2568929A1 (en) *	2004-06-07	2005-12-22	Pfizer Products Inc.	Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060183763A1 (en) *	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
DE102005016634A1 (de)	2005-04-12	2006-10-19	Merck Patent Gmbh	Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
MX2008001605A (es)	2005-08-02	2008-04-14	Irm Llc	Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
MX2008010668A (es) *	2006-02-21	2008-10-01	Amgen Inc	Derivados de cinolina como inhibidores de fosfodiesterasa 10.
US7868177B2 (en)	2006-02-24	2011-01-11	Amgen Inc.	Multi-cyclic compounds and method of use
WO2007129183A2 (en) *	2006-05-02	2007-11-15	Pfizer Products Inc.	Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
US8236823B2 (en)	2006-10-27	2012-08-07	Amgen Inc.	Multi-cyclic compounds and methods of use
ES2360014T3 (es) *	2006-12-21	2011-05-31	Pfizer Products Inc.	Sal succinato de 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol-3-il)-fenoxi)metil)quinolina.
AU2008315746A1 (en)	2007-10-25	2009-04-30	Astrazeneca Ab	Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
WO2009081259A1 (en)	2007-12-21	2009-07-02	Pfizer Inc.	Phenoxy-pyridyl derivatives
AU2009271414A1 (en)	2008-06-20	2010-01-21	Metabolex, Inc.	Aryl GPR119 agonists and uses thereof

2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en not_active Ceased
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
- 2009-11-16 RS RS20120569A patent/RS52598B/sr unknown
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Withdrawn
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 HR HRP20130054AT patent/HRP20130054T1/hr unknown
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
2011
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
2012
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown

Also Published As

Publication number	Publication date
NZ592508A (en)	2013-04-26
PE20110581A1 (es)	2011-09-03
CL2011001094A1 (es)	2011-11-11
EP2364308A1 (en)	2011-09-14
US20110160182A1 (en)	2011-06-30
US20100137278A1 (en)	2010-06-03
CA2742993C (en)	2015-01-20
US8329700B2 (en)	2012-12-11
PT2364308E (pt)	2013-01-08
AU2009313768A1 (en)	2010-05-20
IL212687A0 (en)	2011-07-31
PL2364308T3 (pl)	2013-03-29
HRP20130054T1 (hr)	2013-02-28
HK1161251A1 (en)	2012-08-24
EA201100748A1 (ru)	2011-10-31
US8053438B2 (en)	2011-11-08
CN102300860A (zh)	2011-12-28
MA32889B1 (fr)	2011-12-01
ES2397218T3 (es)	2013-03-05
EP2364308B1 (en)	2012-10-24
SMT201200061B (it)	2013-01-14
CY1113680T1 (el)	2016-06-22
CN102300860B (zh)	2014-08-27
SI2364308T1 (sl)	2013-01-31
US20120277209A1 (en)	2012-11-01
BRPI0922095A2 (pt)	2019-09-24
US8247418B2 (en)	2012-08-21
EA019206B1 (ru)	2014-01-30
US20110160202A1 (en)	2011-06-30
CR20110326A (es)	2011-07-28
CO6382157A2 (es)	2012-02-15
CA2742993A1 (en)	2010-05-20
AU2009313768B2 (en)	2013-01-10
KR20110083746A (ko)	2011-07-20
TWI396689B (zh)	2013-05-21
MX2011005100A (es)	2011-05-30
AR074358A1 (es)	2011-01-12
RS52598B (sr)	2013-04-30
TW201030006A (en)	2010-08-16
JP5746972B2 (ja)	2015-07-08
WO2010057121A1 (en)	2010-05-20
TN2011000221A1 (en)	2012-12-17
JP2012508776A (ja)	2012-04-12

Publication	Publication Date	Title
DK2364308T3 (da)	2013-02-04	Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
DK3354650T3 (da)	2022-05-30	Forbindelser der er nyttige som inhibitorer af ATR-kinase
CY2017042I1 (el)	2018-04-04	Ενωσεις πυρρολοπυριμιδινης ως αναστολεις cdk
DK2315756T3 (da)	2014-10-13	1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2139892T3 (da)	2011-12-12	Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK1981875T3 (da)	2014-07-14	Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK2010498T3 (da)	2011-02-14	Syntese af acylaminoalkenylenamider, der kan anvendes som substans P-antagonister
DK2346888T3 (da)	2013-03-25	Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
DK2421537T3 (da)	2015-06-22	Pyrazolylaminopyridiner som inhibitorer af FAK
DK2021335T3 (da)	2011-09-05	Heterocykliske forbindelser som C-FMS-kinasehæmmere
SMT201600267B (it)	2016-08-31	Inibitori di syk imidazopirazinici
DK2300013T4 (da)	2025-02-03	Phosphorderivater som kinasehæmmere
DK2010496T3 (da)	2010-11-08	4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
DK2414362T3 (da)	2014-09-22	Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
DK2350075T3 (da)	2014-05-26	Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
SMT201400154B (it)	2015-01-15	Composti di triazolopiridina come inibitori di chinasi pim
CR10369A (es)	2009-01-09	Pyrimidine derivatives as pi3k inhibitors
DK2389382T3 (da)	2013-07-08	Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
DK2346321T4 (da)	2022-08-08	Sammensætning til forbedring af effektiviteten af herbicider
DK2318389T3 (da)	2013-09-30	Pyridazinderivater som SMO-inhibitorer
DK3106463T6 (da)	2020-02-24	Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
DK2046767T3 (da)	2015-06-22	Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
BRPI0809974A2 (pt)	2014-10-07	Compostos de pirimidina hidrazida como inibidores de pgds
DK2220070T3 (da)	2011-07-04	2-benzylpyridazinonderivater som Met-kinaseinhibitorer